Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegargiminase - Polaris Pharmaceuticals

Drug Profile

Pegargiminase - Polaris Pharmaceuticals

Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 09 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Memorial Sloan-Kettering Cancer Center; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
  • Class Antineoplastics; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Mesothelioma; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver cancer
  • Phase II/III Mesothelioma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-Hodgkin's lymphoma; Small cell lung cancer; Soft tissue sarcoma
  • Phase I Gastrointestinal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uveal melanoma
  • Preclinical Sarcoma
  • No development reported Bladder cancer; Breast cancer; Cancer; Glioblastoma; Lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Viral infections

Most Recent Events

  • 31 May 2019 Updated efficacy and adverse events data from a phase I trial in Non-squamous non-small cell lung cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 16 Apr 2019 Phase-I clinical trials in Uveal melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (IM) (NCT03922880)
  • 31 Aug 2018 Polaris completes a phase I trial in Prostate cancer (Late-stage disease, Combination therapy, Hormone-refractory, Second-line therapy or greater, Metastatic disease) in USA (IM) (NCT01497925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top